ChartMillAugust 6, 2026 at 8:53 AM NY29 days ago
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance
Collegium Pharma Q2 beats EPS but misses revenue; cuts FY product revenue guidance, stock falls ~11%. ADHD growth offsets pain portfolio weakness.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — ChartMill
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill2 hours ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo3 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo3 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo3 hours ago